VTVT
What one share of vTv Therapeutics holds
Pharmaceutical Preparations
We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399), is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D).
vTv Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.97 |
|---|---|
| Profit | −$0.38 |
| Cash and investments | $6.97 |
| Book value | $6.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $2.56 | −$8.29 | $0.00 | −$12.32 | — | −$6.22 |
| 2022 | $1.05 | −$9.98 | $0.01 | −$8.35 | — | −$5.59 |
| 2023 | $0.00 | −$9.71 | $0.00 | −$9.15 | — | −$11.83 |
| 2024 | $0.18 | −$3.20 | $0.00 | −$4.39 | — | $2.11 |
| 2025 | $0.00 | −$3.20 | — | −$3.00 | — | $7.64 |